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Transdermal Treatment Options for
Neurological Disorders
Impact on the Elderly
Lorenzo Priano,1 Maria Rosa Gasco2  and Alessandro Mauro1,3 
1 Department of Neurology and Neurorehabilitation, IRCCS Istituto Auxologico Italiano,
Piancavallo, Italy
2 Nanovector srl, Turin, Italy
3 Department of Neurosciences, University of Turin, Turin, Italy
As people grow old, their need for medications increases dramatically becauseAbstract
of the higher incidence of chronic pain, diabetes mellitus, cardiovascular and
neurological diseases in the elderly population. Furthermore, the elderly require
special consideration with respect to drug delivery, drug interactions and adher-
ence. In particular, patients with chronic neurological diseases often require
multiple administration of drugs during the day to maintain constant plasma
medication levels, which in turn increases the likelihood of poor adherence.
Consequently, several attempts have been made to develop pharmacological
preparations that can achieve a constant rate of drug delivery.
For example, transdermal lisuride and apomorphine have been shown to
reduce motor fluctuations and duration of ‘off’ periods in advanced Parkinson’s
disease, while rotigotine allows significant down-titration of levodopa without
severe adverse effects. Thus, parkinsonian patients with long-term levodopa
syndrome or motor disorders during sleep could benefit from use of transdermal
lisuride and apomorphine. Moreover, transdermal dopaminergic drugs, particular-
ly rotigotine, seem the ideal treatment for patients experiencing restless legs
syndrome or periodic limb movement disorder during sleep, disorders that are
quite common in elderly people or in association with neurodegenerative diseases.
Unlike dopaminergic drugs, transdermal treatments for the management of
cognitive and behavioural dysfunction in patients with Parkinson’s disease and
Alzheimer’s disease have inconsistent effects and no clearly established role.
Nevertheless, because of their favourable pharmacological profile and bioavai-
lability, the cholinesterase inhibitors tacrine and rivastigmine are expected to
show at least the same benefits as oral formulations of these drugs, but with fewer
severe adverse effects.
Transdermal delivery systems play an important role in the management of
neuropathic pain. The transdermal lidocaine (lignocaine) patch is recommended
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as first-line therapy for the treatment of postherpetic neuralgia. Furthermore, in
patients with severe persistent pain, transdermal delivery systems using the
opioids fentanyl and buprenorphine are able to achieve satisfactory analgesia with
good tolerability, comparable to the benefits seen with oral formulations.
Transdermal administration is the ideal therapeutic approach for chronic
neurological disorders in elderly people because it provides sustained therapeutic
plasma levels of drugs, is simple to use, and may reduce systemic adverse effects.
Several transdermal delivery systems are currently under investigation for the
treatment of Parkinson’s disease, Alzheimer’s disease and neuropathic pain.
Although most transdermal delivery systems treatments cannot be considered as
first-line therapy at present, some of them provide clear advantages compared
with other routes of administration and may become the preferred treatment in
selected patients. In general, however, most transdermal treatments still require
long-term evaluation in large patient groups in order to optimise dosages and
evaluate the actual incidence of local and systemic adverse effects.
Transdermal drug delivery systems (TDS) have under investigation for neurological diseases, with a
several advantages over parental and oral routes of particular focus on Parkinson’s disease (PD) and
administration, and it is the elderly who can derive restless legs syndrome (table I), Alzheimer’s disease
the greatest benefits.[1] This is particularly true when (AD) [table II] and neuropathic pain (table III).
a chronic neurological disorder is present, because Current available databases (MEDLINE from the
motor or cognitive deficits may overlap with the US National Library of Medicine, IngentaConnect)
impairments in daily living activities typical of ad- were used for the literature search, with the main
vanced age. In this context, TDS may circumvent key words being: neurological diseases, movement
the patient’s unwillingness or incapability to swal- diseases, Parkinson’s disease, Alzheimer disease,
low oral preparations and remove the discomfort dementia, restless legs syndrome, periodic limb
associated with multiple intramuscular injections or movements, pain, transdermal, dermal, patch and
intravenous infusions. Transdermal administration elderly.
of drugs also prevents problems associated with
hepatic first-pass metabolism, poor absorption from 1. Motor Fluctuations in
the gastrointestinal tract and variable bioavailabili- Parkinson’s Disease
ty. Constant plasma concentrations may be achieved
as a result of rate-controlled delivery of particular
1.1 Motor Fluctuations and Continuouspreparations, even when the drug has a short elimi-
Dopaminergic Stimulation
nation half-life. As a consequence, frequency of
administration may be significantly reduced, poten- The management of motor fluctuations in ad-
tially improving adherence in elderly people. The vanced PD still represents a major problem.[43-45]
site of drug delivery can also be regularly changed, When the disease is recognised and dopaminergic
thereby reducing the risk of local adverse events. therapy initiated, patients usually show sustained
This review examines the efficacy and tolerabili- improvement after administration of medication
ty of transdermal drug administrations currently without any deterioration in motor function.[46,47]
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Table I. Transdermal delivery systems using dopaminergic drugs for the management of Parkinson’s disease (PD), restless legs syndrome (RLS) and periodic limb movement
disorder (PLMD) during sleep
Drug Use Absorption Dosing regimen and Notes Main adverse effects References
approximate release rate
Bromocriptine Preclinical studies in Passive, use of 2
animals penetration enhancers
Lisuride Add-on therapy in PD Passive 2–5 µg/cm2/h Reduction in motor Transient skin irritation 3
(pilot study) fluctuations
Severe RLS (controlled 3mg per patch; 7 µg/h Improvement according Transient skin irritation 4
pilot study) to RLS severity scales
and actigraphy
assessments
Apomorphine Add-on therapy in PD Iontophoresis and use 15 mmol/L per patch; Improvements in rigidity, Tingling and itching, 5
(pilot study) of percutaneous 98.3 ± 12.1 nmoL/cm2/h tremor and dyskinaesias slight erythema
absorption enhancers during or after current
application
Add-on therapy in PD Passive diffusion from 40mg per patch; 88 µg/ Reduction in total Sleepiness, transient 6
(pilot study) microemulsion cm2/h duration of ‘off’ periods nausea, transient skin
irritation
PLMD in PD (pilot study) Passive diffusion from 40mg per patch Reduction in periodic Transient skin irritation 7
microemulsion limb movement index
and reduction in sleep
instability
Rotigotine Add-on therapy in early Passive 4.5–18mg per patch Improvements in motor Sleepiness, mild 8-12
and advanced PD scores and activities of nausea and vomiting,
(multicentre controlled daily living scores on the dizziness, mild skin
studies) UPDRS; down-titration of irritation
daily levodopa dose
allowed
Moderate and severe 4.5mg Improvement according Mild skin irritation 13
RLS (multicentre to RLS severity scales
controlled study)
UPDRS = Unified Parkinson’s Disease Rating Scale.
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Table II. Transdermal drug delivery systems for the management of cognitive and behavioural dysfunctions in Alzheimer’s disease (AD) and Parkinson’s disease (PD)
Drug Use Absorption Dosing regimen Notes Main adverse effects References
Physostigmine Probable AD (multicentre Passive 30–60mg Not superior to placebo after Nausea, vomiting, 14,15
controlled studies) 24 weeks, probably because abdominal cramps,
of low dosages headache
Tacrine Pilot study in healthy Drug release with Total dose 64mg Constant and clinically Transient skin irritation, 16,17
adults iontophoresis from ion- significant plasma pinching
exchange fibre discs concentrations achieved
during iontophoresis
Rivastigmine Preclinical study in Passive 18–54mg Bioavailability 20–40 times Skin irritation 18
animals greater than oral
administration
Patients with AD or mild No deterioration in fine 19
cognitive impairment motor skills
(pilot study)
Probable AD (phase III Efficacy in relation to 20,21
study) cognitive dysfunctions still
under evaluation
Nicotine AD with mild-to-moderate Passive 14–21 mg/day No efficacy in relation to Nausea, dizziness, sleep 22
dementia (controlled memory deficit, verbal disturbance
study) fluency, attention or
psychomotor speed
AD with mild-to-moderate 5–10 mg/day Improvement in attentional 23
dementia (controlled performance; performances
study) on other tests measuring
motor and memory function
not improved
Nondemented aged 5–10 mg/day Inconsistent changes in 24
people at risk for relation to verbal learning,
dementia (pilot study) delayed recall and word
retrieval; findings
inconclusive
Nondemented PD 7–21 mg/day Contradictory results in Poorly tolerated because 25-28
patients relation to motor symptoms; of nausea, vomiting,
no changes on cognitive dizziness, increased
tasks blood pressure, intestinal
cramps
17β-estradiol Postmenopausal woman Passive 0.05–0.10 mg/day Improvements in attention Well tolerated 29,30
with AD (controlled and verbal memory;
studies) reduction of plasma
concentration of toxic β-
amyloid fragments (Aβ40)
Men with advanced AD No effect on aggressive Rebound in aggressive 31
(controlled study) behaviour behaviour after patch
removal
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However, after a variable period of time the duration the dopamine receptor agonists, apomorphine and
lisuride have proved to be useful when administeredof effectiveness of a single dose of levodopa pro-
by subcutaneous continuous infusion.[61,62] Howev-gressively decreases and it becomes necessary to
er, even though some patients can tolerate this treat-increase the number of administrations to maintain
ment for years, difficulties relating to needle man-the benefit. This condition characterises the ‘long-
agement and local or systemic adverse effects suchterm levodopa syndrome’, which may also include
as nausea, orthostatic hypotension and skin reac-choreiform involuntary movements that typically
tions[61,62] may limit the widespread use of this tech-appear at peaks of levodopa effectiveness.[48-50]
nique, especially in the elderly.Pharmacodynamic and pharmacokinetic factors
have been hypothesised to explain the genesis of
1.2 Continuous Dopaminergic Stimulation
motor fluctuations in patients with PD taking
with Transdermal Dopaminelevodopa: impaired gastric emptying with delay in
Agonist Preparationslevodopa reaching its absorptive site,[51,52] interfer-
ence of dietary proteins with levodopa absorp- Currently, there is increasing interest in the po-
tion,[53] inadequate dopamine storage following pro- tential role of TDS in the treatment of PD, as this
gressive death of dopaminergic neurons as part of route of administration can be considered the ideal
the neurodegenerative process, pulsatile dopamine means to achieve prolonged plasma levels of drugs
receptor stimulation associated with exogenous and continuous dopaminergic stimulation with little
discomfort for patients.[63] Several TDS have beenlevodopa administration,[54,55] and upregulation of
used to deliver a variety of medications, includingnearby glutamate receptors and consequent overac-
sex hormones and analgesics,[64,65] with resultanttivity of striatal neurons driven by cortical gluta-
achievement of steady-state dose-linear plasmamatergic firing.[56] In order to prevent the occurrence
levels of the delivered drugs. Unfortunately,of this pulsatile stimulation, several strategies have
levodopa is not a good candidate for transdermalbeen proposed to provide a more continuous deliv-
administration because of its poor solubility andery of drug and constant levels of striatal dopamin-
stability. However, several transdermal preparationsergic activation. These strategies include levodopa
with dopamine agonists have been studied, althoughadministration on an empty stomach or at least sepa-
only a few of these still seem promising for clinicalrated from dietary proteins; use of medications that
use (see section 1.2.2). Administration of most ofhasten gastric emptying such as cisapride and
the latter agents is based on passive diffusion of adomperidone;[57] administration of controlled-re-
soluble drug through the skin and capillaries, al-lease levodopa preparations or drugs inhibiting
though in some cases drug passage across the skin islevodopa metabolism, such as monoamine oxidase
enhanced by the application of a small electric cur-inhibitors and catechol-O-methyl-transferase inhibi-
rent (transdermal iontophoretic transport). Othertors;[58,59] and use of constant intravenous infusion
promising preparations use specific microemulsionsor duodenal delivery of levodopa after placement of
that permit a significant increase in transdermala percutaneous endoscopic gastrostomy tube.[60]
diffusion of the agent included (see section 1.2.2).Nevertheless, while these therapeutic approaches
can reduce ‘wearing-off’ phenomena in some pa- 1.2.1 Insufficiently Effective Transdermal Systems
tients, further studies are needed to demonstrate The first attempts to develop TDS with dopamine
their effectiveness in providing constant receptor agonists date back to the mid-1980s, when nax-
stimulation and preventing motor fluctuations. Of agolide [(+)-4-propyl-9-hydroxynaphthoxazine
 2006 Adis Data Information BV. All rights reserved. Drugs Aging 2006; 23 (5)
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(PHNO)], a potent dopamine D2 receptor agonist, duced in clinical trials only recently, has undergone
was proposed for transdermal administration be- wider testing as a TDS treatment for PD.
cause of its solubility in lipid and aqueous medi- Apomorphine (6a-β-aporphine-10,11-diol) is a
um.[66] A few years later, the antiparkinsonian effi-
well-known potent agonist at D1 and D2 receptors
cacy of naxagolide in 1-methyl-4-phenyl-1,2,3,6-
and a very useful adjunctive medication in parkin-
tetrahydropyridine (MPTP)-treated squirrel
sonian patients with refractory motor fluctua-
monkeys[67] and in parkinsonian patients was report- tions.[72,73] However, despite its favourable pharma-
ed.[68,69] Plasma concentrations of naxagolide were
cological characteristics, clinical use of apomor-
shown to begin to rise 4–6 hours after patch applica- phine in the treatment of PD has been somewhat
tion and reach a steady state by 24 hours. This limited by its pharmacokinetic profile, i.e. short
pharmacokinetic profile was attributed to the lag half-life of approximately 30 minutes, rapid clear-
time needed for skin permeation and the reservoir
ance from plasma, absence of storage or retention in
action of subcutaneous tissues. Despite these pre- brain regions, poor bioavailability (5%) and high
liminary results, sufficient evidence for the efficacy first-pass metabolism after oral administration.[74]
of this preparation as monotherapy was not obtained To overcome these limitations, subcutaneous, sub-
to justify further clinical studies. lingual, rectal and intranasal routes of administra-
More recently, transdermal administration of the tion were studied,[75-78] but none of these demon-
D2 receptor agonist nonergot piperazine derivate strated the capability for prolonged dopaminergic
piribedil in a marmoset MPTP model of PD resulted stimulation. Only subcutaneous administration of
in reversal of motor deficits without significant ad- apomorphine by means of a microinfusor can pro-
verse effects.[70] Unfortunately, in a double-blind, duce constant therapeutic plasma levels of the
placebo-controlled study of 27 patients with idio- drug.[79,80] However, this treatment may become im-
pathic PD, TDS with piribedil did not prove effica- practical for chronic use in most patients because of
cious with respect to either the main endpoint (Uni- development of local subcutaneous nodules or sys-
fied Parkinson’s Disease Rating Scale [UPDRS] temic adverse effects (e.g. hypotension, nausea,
motor score) or the secondary endpoints (rigidity, sleepiness and hallucinatory phenomena), especially
bradykinesia, postural and resting tremor scores), in the elderly.[81]
probably because of the low plasma concentrations
In order to exploit the favourable pharmacologi-
achieved (<10 ng/mL).[71] Technical problems relat-
cal characteristics of apomorphine and overcome
ed to the largeness of the patch required to deliver
the pharmacokinetic limitations of the drug, two
adequate dosages of the drug stopped further devel-
different approaches have been proposed for trans-
opments of this TDS.
dermal delivery. The first approach attempted to
exploit the potential of transdermal iontophoresis to
1.2.2 Promising New Transdermal Systems deliver apomorphine continuously into systemic cir-
culation at a well controlled rate (current-dependentAt present, transdermal administration of four
delivery system).[82-84] Studies evaluating this ap-dopamine agonists has been evaluated with results
proach demonstrated that delivery of apomorphinefrom preliminary in vivo studies that warrant further
by the transdermal route was feasible and that theefforts to confirm their effectiveness. Three of these,
rate of delivery could be controlled by modulatingapomorphine, bromocriptine and lisuride, are well
current density. However, the plasma concentrationsknown dopamine agonists generally administered in
achieved were at the lower limit of the therapeuticpast years via other routes, whereas rotigotine, intro-
 2006 Adis Data Information BV. All rights reserved. Drugs Aging 2006; 23 (5)
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range (<10 ng/mL).[82-84] Recently, iontophoresis transport of apomorphine through the skin in this
was applied after skin pretreatment for 1 hour with preparation. In a group of 21 patients affected by PD
an aqueous mixture of three surfactants (acting as a and motor fluctuations, this preparation provided
percutaneous absorption enhancer) to overcome the therapeutic apomorphine plasma levels (>15 ng/
limitations of iontophoretic delivery.[5] Pretreatment mL) for 12 hours, corresponding to the period of
of the skin with this absorption enhancer, compared time the patch was maintained on the skin.[6] The
with iontophoresis alone, resulted in a 2-fold in- total duration of ‘off’ periods decreased by about
crease in iontophoretic transport of apomorphine in 50% compared with levodopa treatment alone and
vitro, an approximate 10% increase in bioavailabili- by about 30% compared with levodopa plus oral
ty and a near 2-fold increase in the percentage of dopamine agonist therapy. Systemic adverse effects
responder patients. Moreover, the concentration- (sleepiness, nausea, mild orthostatic hypotension)
time profiles of apomorphine after transdermal and local transient mild erythema occurred in about
iontophoretic administration with pretreatment with 10% and 70% of patients, respectively, but the over-
percutaneous absorption enhancer were similar to all tolerability was good and only one patient needed
those obtained with constant intravenous infusions. to discontinue treatment because of severe nausea
However, pretreatment was associated with larger not controlled by domperidone.[6] These preliminary
interindividual variations in apomorphine profiles, results seem encouraging and suggest that this prep-
which suggests that this approach is not yet optimal aration could be a useful treatment for PD patients,
and needs further improvement. Nevertheless, no particularly for those experiencing uncontrolled
clinically relevant systemic adverse effects were ‘wearing-off’ and prolonged ‘off’ phenomena. Use
described and only brief sensations such as tingling of a patch on the skin that can be easily applied by
and itching without pain during application of the patients or relatives together with a long duration of
current and a transient slight erythema were report- clinical efficacy might be particularly advantageous
ed.[5] for elderly subjects, especially during the night, and
would also be associated with little discomfort whileThe second approach to transdermal delivery of
reducing the number of oral levodopa administra-
apomorphine consisted of the development of a nov-
tions required. Conversely, because about 1 hour is
el pharmaceutical preparation of apomorphine dis-
required for this preparation to achieve therapeutic
solved in a thickened microemulsion.[85] In this
plasma concentrations of apomorphine, it would notpreparation, apomorphine was present in the
appear to be the ‘ideal’ preparation for rapid relief of
microemulsion as an ion pair complex with octa-
the ‘off’ condition: in this case, apomorphine ad-
noate in order to increase its lipophilicity and dimin-
ministered by the subcutaneous route, which pro-ish its dissociation from the microemulsion. The
vides the most rapid absorption, still remains thedrug was completely dissolved in the microemul-
best choice. However, because local adverse effects
sion and relatively high concentrations could be
are likely to be a major problem arising with chronic
obtained as a result of the supersolvent properties of
treatment, this preparation requires further investi-
microemulsions. The dispersed phase, also acting as
gation in a larger group of patients and greater
a reservoir, made it possible to maintain an almost
optimisation of apomorphine dosages and applica-
constant concentration of apomorphine in the con-
tion areas.tinuous phase and pseudo-zero-order kinetics could
thus be achieved in vitro.[85] The formation of an ion Bromocriptine, a semi-synthetic ergot alkaloid
pair is presumably the main reason for the facilitated with a preferential effect on the D2 receptor subtype,
 2006 Adis Data Information BV. All rights reserved. Drugs Aging 2006; 23 (5)
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has been widely used in previous years for the (from 3 weeks up to 27 weeks).[9,10] Rotigotine at
treatment of PD in oral formulations. However, sim- dosages of 13.5–36 mg/day was associated with
ilarly to apomorphine, the pharmacokinetics of statistically significant improvements in motor
bromocriptine administered via the oral route are not scores and activities of daily living scores on the
favourable because of the drug’s low bioavailability UPDRS, and a dosage of 18 mg/day was reported to
as a result of the hepatic first-pass effect.[86] Alterna- be well tolerated by about 80% of patients.[9-11]
tive delivery routes such as intramuscular[87] or vagi- Application site reactions, occurring in about half of
nal application[88] have been reported but also shown patients, and systemic adverse effects (primarily
to be expensive or not practical for chronic use. A nausea, vomiting and somnolence), occurring in
transdermal formulation of bromocriptine using a about one-fifth of patients, were generally mild,
polycationic polymer and penetration enhancers has suggesting that doses higher than those used in these
been tested in rabbit skin, showing that sufficient
studies could be given.[10,11] Transdermal delivery of
penetration of the drug could be achieved.[2] Howev-
rotigotine was shown to provide constant blood
er, it should be noted that rabbit tissue is more levels of drug over 24 hours and this sustained
permeable than human skin, and further studies are dopaminergic stimulation allowed down-titration of
expected to verify if this formulation will work in
the daily levodopa dose by >50%, with maintenance
the same way with human skin.
of efficacy on motor symptoms even in subjects
Recently, a pilot study of a novel formulation of with advanced PD. An overall beneficial effect of
another potent D2 receptor agonist, lisuride, demon- this transdermal dopamine agonist on drug-induced
strated adequate drug release in mice and encourag- dyskinesias when given in conjunction with
ing results as add-on therapy in eight patients with levodopa was also described.[9,12]
advanced PD.[3] The additional lisuride patch appli-
These encouraging preliminary pharmacokinetic,cation was reported to significantly improve motor
pharmacodynamic and efficacy data for dopaminefunction according to a patient’s self-rating scale,
agonists administered via the transdermal routewith mild adverse effects in half of the patients
mandate continued exploration of this therapeuticresulting in transient skin irritations.[3]
modality, particularly in the elderly, given the rela-
Rotigotine, a novel lipid-soluble, non-ergot D3/ tively simple administration, lack of invasiveness,D2/D1 receptor agonist, has undergone more testing long duration of clinical benefits and good tolerabil-
than any other dopamine agonist as a transdermal
ity associated with this approach. At present, thesepreparation for PD treatment. Rotigotine has been
preparations have been used as adjuvant therapy in
shown to be effective in preclinical studies with
advanced PD, but future studies will define whetheranimal models of PD[89,90] and, formulated as a skin
continuous dopaminergic stimulation from the startpatch, has also been shown to be a promising treat-
of antiparkinsonian therapy is efficacious and pre-ment in recent clinical studies.[8-12] In these studies,
vents motor fluctuations typical of intermittent ther-administration of rotigotine led to significant im-
apy. Because orthostatic hypotension, which is notprovement in motor symptoms both in advanced and
uncommon in the elderly, hallucinations and persis-early stages of PD, although the optimal dose has yet
tent local erythema could prove limitations to use ofto be determined because of use of two different
this type of therapy in the elderly, prudent selectionTDS (the more recent system increased drug deliv-
of patients will be required. However, it must beery 3-fold compared with the earlier patch of the
same size) and different study designs and durations emphasised that a further advantage of transdermal
 2006 Adis Data Information BV. All rights reserved. Drugs Aging 2006; 23 (5)
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therapy consists of the relatively rapid reversibility fects for rotigotine and placebo were similar. Simi-
of adverse effects by patch removal. larly, in a controlled pilot study, symptoms of severe
restless legs syndrome were clearly improved by
2. Restless Legs Syndrome and Periodic lisuride 3mg patch, without clinically relevant ad-
Limb Movement Disorder During Sleep verse effects.[4] Moreover, sleep analysis in 12 PD
patients during night-time transdermal apomorphine
Restless legs syndrome is a frequent cause of treatment revealed a 15% reduction in the periodic
insomnia in the elderly because its incidence in- limb movement index together with a significant
creases sharply with age and it may be associated reduction in sleep instability.[7] Future trials will
with several diseases common in the elderly, such as verify the efficacy of these TDS in the treatment of
neuropathies, iron deficiency, renal failure and periodic limb movement disorder during sleep and,
neurodegenerative diseases. Typically, patients re- as with PD, further efforts will be directed at evalu-
port a history of inability to keep their legs still when ating the optimal dosages and possible adverse ef-
trying to fall asleep because of continuous dysaes- fects associated with prolonged treatment.
thesias, coupled with an urge to get out of bed and
walk around in an attempt to obtain transient relief. 3. Cognitive Dysfunctions in
This syndrome is frequently associated with period- Neurodegenerative Diseases
ic jerks involving the lower limbs during sleep docu-
mented by polysomnography. The consequences of
3.1 Behavioural Problems and Cognitivethis condition include difficulties in sleep onset and
Dysfunctions in Dementiamaintenance, sleep disruption, low sleep efficiency
and daytime excessive somnolence. Behavioural and cognitive problems in
Oral dopamine agonists are the therapy of choice
neurodegenerative disease, primarily AD, are diffi-
for restless legs syndrome and in most patients they
cult to control and are recognised as leading causes
are very efficacious at lower dosages than those for institutionalisation. However, cognitive deficits
used in PD.[91] Nevertheless, some patients with
resulting from progression of degenerative process-
dysaesthesias or periodic limb movements persist-
es, together with advanced age, make repeated ad-
ing through the night may require excessively high
ministration of doses of drug often impracticable.
dosages or may experience only short-lasting bene- Currently available therapies for AD are limited to
fit from oral treatment.[91] Moreover, many patients
cholinergic drugs according to the hypothesis that
may experience symptoms not only at bedtime but
cognitive impairment in AD results from the death
also during the day or according to variable circadi-
or deficit of cholinergic neurons in the basal fore-
an patterns.[92] In these cases, transdermal prepara- brain.
tions of dopamine agonists are expected to be the
best choice. 3.1.1 Anticholinesterase Drugs
In a recent double-blind, placebo-controlled, Studies conducted in the 1980s[93-96] made up the
1-week pilot study, the novel nonergot D2 receptor initial phase of clinical trials that evaluated anticho-
agonist rotigotine, formulated as a skin patch, was linesterase drugs. These studies were designed to
shown to be efficacious in patients with moderate- test the efficacy and safety of physostigmine by oral
to-severe idiopathic restless legs syndrome when and intravenous administration, but the short half-
administered at a dosage of 4.5 mg/day.[13] The skin life of about 30 minutes and rapid hepatic clearance
tolerability of the patches and systemic adverse ef- of the drug proved to be serious disadvantages.[93]
 2006 Adis Data Information BV. All rights reserved. Drugs Aging 2006; 23 (5)
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Unfortunately, more recent trials[14,97-99] using con- study involving ten healthy adults who were given
tacrine 64mg delivered from the ion-exchange fibretrolled-release formulations of physostigmine had
for 3 hours by iontophoresis, and for 1 hour passive-serious methodological problems that did not permit
ly, were also encouraging.[101] Therapeutically rele-the correct identification of responders.[14] In order
vant plasma concentrations of tacrine wereto overcome these limitations, a physostigmine
achieved, the plasma profile reached a plateau aftertransdermal therapeutic system was developed and
the first 30 minutes of current delivery and inter-tested in a large study that included patients with
subject variations were quite small. The flux re-probable AD and mild-to-moderate cognitive im-
mained constant until the current was turned off.pairments.[15] In contrast to expectations, the effica-
Moreover, even during passive permeation, tacrinecy of physostigmine was not superior to placebo in
plasma concentrations decreased slightly as a conse-this study, but, as noted by the investigators, the
quence of formation of a reservoir of the drug in thedoses delivered (up to 60mg) were probably too low
skin. Local irritation was present in all patients andto evaluate efficacy. Physostigmine plasma concen-
was reported to be directly related to the ion-trations showed a high degree of interindividual
tophoretic current density.[101] On the basis of thesevariability without linear correlation with dosages
data, this system appears to be a promising noveland appeared to be insufficient to compensate for
treatment for AD, although the optimal current den-cholinergic deficiencies in brain areas. The very low
sity, possible effects of long treatment on liver func-occurrence of adverse effects was also consistent
tion and clinical efficacy of this approach need to bewith this interpretation.[15] Clearly, modification of
investigated.this patch system is mandatory in order to achieve
Rivastigmine, another acetylcholinesterase in-higher physostigmine plasma concentrations and al-
hibitor, also seems to hold promise for TDS use inlow evaluation of the clinical efficacy of this ap-
neurodegenerative disease. Dermal administrationproach during long-term therapy.
of rivastigmine in animals was associated with a
Similarly to physostigmine, tacrine (1,2,3,4
markedly greater bioavailability than with the oral
tetrahydro-9-acridinamine), a reversible cholinester-
route,[18] and clinical studies in patients are still
ase inhibitor used for AD treatment, has low
under way to verify a possible role in the manage-
bioavailability because of the hepatic first-pass ef-
ment of AD.[19] In particular, a large multicentre,
fect and a relatively short elimination half-life (2–4
controlled, phase III study evaluating the safety and
hours).[100] Moreover, tacrine has the potential for
efficacy of the rivastigmine TDS in patients with
dose-dependent hepatotoxicity and peripheral cho- probable AD, started in 2003, has recently been
linergic adverse effects.[100] Interest in transdermal completed and data will soon be available.[20,21]
delivery of tacrine for AD derives not only from the
possibility of reducing toxicity but also from the 3.1.2 Nicotine
hypothesis that constant levels of tacrine in the brain Demonstration of deficient nicotinic-cholinergic
may maximise its effects on memory enhance- receptor binding in AD brain[102] in the past decade
ment.[16] In a recent preclinical study,[17] control of encouraged studies investigating the efficacy of the
transdermal drug delivery was obtained using a nov- alkaloid nicotine in the management of behavioural
el ion-exchange fibre and iontophoresis. The ion- problems in AD patients. Moreover, recent research
exchange fibres acted as a drug reservoir, control- has indicated that nicotine can limit verbal outbursts
ling the release and iontophoretic transdermal deliv- in Tourette syndrome[103] and reduce the inattentive-
ery of the drug. Pharmacokinetic data from a pilot ness of attention-deficit hyperactivity disorder.[104]
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Short-term nicotine injections were found to im- ments. Higher doses of nicotine or combining nico-
tine with other therapies may provide greater effica-prove attentional performance in AD,[105] but could
cy. Interestingly, a potential therapeutic role fornot be of practical use in the long-term treatment of
nicotine treatment in nondemented aged patients atAD. However, transdermal nicotine patches offer a
risk of dementia has recently been suggested, al-way of delivering measured doses of nicotine in a
though further studies are needed to confirm thesesafe fashion and for a longer period of time.
data.[24] In this study, significant changes in verbalPreliminary reports of use of transdermal nico-
learning, object learning, delayed recall and wordtine patches for AD did not provide homogeneous
retrieval were reported, particularly in patients at the
results. One study described three AD patients and
lower end of baseline test performance on the tasks
one patient with vascular dementia who became less
used.
agitated during treatment with transdermal nicotine
In the future development of nicotinic treatments,7–14mg and experienced deterioration of their
animal models will become important for investigat-
clinical state when the patch was discontinued.[106]
ing the neurobiological basis of nicotine involve-However, use of complicated medical regimens, the
ment in cognitive functions. Local nicotine infusion
absence of standard assessment tools and the small
in rats showed that the hippocampus and amygdala
numbers of patients studied prevented the investiga-
are important substrates for nicotine effects on
tors from drawing conclusions. In another pilot
working memory function.[108,109] Both α7 and α4β2
study,[107] treatment with a nicotine patch for 8 days
nicotine receptors have been reported to be involvedin six patients with probable AD was reported to in working memory, and nicotine interactions withimprove learning but did not significantly affect dopaminergic and glutamatergic systems may also
memory, behaviour and global cognition. Sustained play a role.[110] At the molecular level, nicotinic
administration of nicotine appeared to be safe and
receptor agonists have been shown to induce long-
well tolerated, although a significant decrease in
term potentiation, as shown by strengthening of
sleep was reported. Similarly, a double-blind, place-
synaptic connections associated with learning and
bo-controlled, crossover study[22] focusing on short-
memory formation and enhanced neurotransmitter
term memory in 18 AD patients with mild-to-mod-
release.[111] The study of neural nicotinic mecha-
erate dementia did not find any significant differ-
nisms related to cognitive functions may lead to the
ence between placebo and treatment with a dermal development of more selective nicotinic analogues
nicotine plaster at dosages of 14–21 mg/day for 4 for the treatment of behavioural and cognitive dys-
weeks. A more recent double-blind, placebo-con- functions with fewer adverse effects.
trolled study[23] in eight AD patients with mild-to-
moderate dementia, consisting of two periods of 3.1.3 Muscarinic Receptor Agonists
4-week transdermal nicotine up to 10 mg/day sepa- Similarly to nicotine agonists, muscarinic cholin-
rated by a 2-week washout period, reported a signifi- ergic drugs, particularly muscarinic M1 agonists, are
cant improvement in attentional performance, but potentially useful for AD treatment and may reduce
did not show improved performance in other tests the need for free choline in acetylcholine synthesis.
measuring motor and memory functions. The dis- In AD, cholinergic neurons are believed to compen-
crepancies among these reports may reflect the sate for a deficiency of choline required for acetyl-
small number of patients studied, which limits the choline synthesis by degrading membrane phospha-
statistical power of these studies to detect more tidylcholine.[112] In a recent placebo-controlled
subtle but clinically significant cognitive improve- study[113] that analysed brain proton magnetic
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resonance spectroscopy in patients with mild-to- latter improved rapidly after 1 week of treatment,
moderate AD receiving a 16-week treatment with and the improvement was positively correlated with
transdermal xanomeline, it was claimed that this plasma levels of estradiol. Moreover, the improve-
M1/M4 receptor agonist improved both the cognitive ments in attention and memory decreased as soon as
deficits and behavioural symptoms of AD. These treatment was discontinued. The dosages used were
interesting preliminary data suggested a relationship similar to those commonly employed to treat symp-
between levels of parietal lobe grey-matter cytosolic toms associated with menopause, but with the ad-
choline, the precursor pool for acetylcholine synthe- vantages of achieving steady-state plasma levels of
sis, and cognitive performances during treatment. the drug similar to those found during the early to
Further large-scale studies[114] are under way to con- mid-follicular phase of the menstrual cycle and low
firm the capacity of xanomeline to attenuate the risks of venous thrombosis and hypertension. Other
membrane degradation process and to define its investigators have also reported similar beneficial
safety and efficacy profile in the treatment of AD. effects for estrogen on other selective cognitive do-
mains;[120,121] conversely, however, some studies
3.1.4 Estrogens
were unable to demonstrate persistent effects of
Besides cholinergic drugs, evidence from
estrogen on cognitive functions.[122,123] These incon-
clinical, epidemiological and basic neuroscience re-
sistencies may reflect the use of different cognitive
search suggests that estrogens should modify the
assessment tools, different potencies of estrogen
pathobiology of AD and improve some symptoms of formulations or qualitatively different population
the disease. Some studies have suggested that hor-
samples. Nevertheless, interest in HRT has been
mone replacement therapy (HRT) has cognition-
reinforced by the demonstration that transdermal
enhancing effects in women with AD.[115,116] Es- 17β-estradiol 0.10 mg/day administered for 8 weeks
tradiol has shown a variety of neurotrophic and
to HRT-naive postmenopausal women with proba-
neuroprotective properties, increases the function of
ble AD reduced the plasma concentration of toxic β-
several neurotransmitters, increases cerebral blood
amyloid fragments (Aβ40) associated with AD pa-flow, facilitates long-term potentiation in the hippo-
thology.[30] Although a clear correlation between
campus and has antioxidant activities.[117] More-
Aβ40 concentrations and cognitive status is lacking,
over, cell-culture studies support the ability of es-
these data are particularly interesting because poten-tradiol to favourably alter the processing of amy-
tially this treatment could slow disease progressionloid-precursor protein, the protein that plays the
by reducing β-amyloid toxicity and delaying senile
main role in the pathobiology of AD.[118] Unfortu-
plaque formation. In this context, where prolonged
nately, contradictory reports do not allow a definite
treatment is needed, transdermal administration ofconclusion to be drawn as to whether or not HRT
hormone appears the best option.could reduce the risk of development of dementia in
Large studies of the efficacy of estrogens via thepostmenopausal women, probably because of the
transdermal route in males with dementia are stillheterogeneity of therapeutic protocols and popula-
lacking. A single 8-week, randomised, controlledtions studied.[119] A placebo-controlled, double-
study investigated the efficacy and tolerability ofblind, pilot study[29] in postmenopausal women with
transdermal estrogen patches as adjunctive treat-mild-to-moderate AD treated for 8 weeks with 17β-
ment for aggressive behaviour in 27 male patientsestradiol 0.05 mg/day, delivered via a skin patch,
with advanced dementia.[31] Use of the patch wasprovided clinical evidence of a specific improve-
well tolerated and produced a significant rise inment in attention and verbal memory. Indeed, the
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serum estrogen but not a decrease in serum testoster- ment was also poorly tolerated because of acute
one. Aggressive behaviour was not influenced by adverse effects such as dizziness, nausea and in-
estrogen treatment, but a rebound in aggressive be- creased blood pressure, with about 60% of patients
haviour after patch removal was described. This withdrawing from therapy. The poor tolerability and
finding is difficult to interpret, and larger studies are lack of efficacy might have been related to a possi-
therefore needed to verify any effect of transdermal ble lack of specificity of nicotine in targeting critical
estrogen treatment in males with dementia. nicotinic receptors involved in the pathophysiology
of PD, suggesting the need for more selective nico-
tine agonists for PD treatment.3.2 Cognitive Dysfunctions in
Parkinson’s Disease
4. Neuropathic Pain and
Studies assessing the efficacy of nicotine in PD Limb Dysaesthesias
patients have produced contradictory results. The
rationale for using this drug derives from animal Chronic pain syndromes and dysaesthesias
studies that showed decreased dopaminergic cell caused by peripheral neuropathies are a common
loss in the MPTP experimental model[124] and complaint in the elderly and may result in poor
slowed age-associated dopaminergic receptor quality of life and depression. In particular, pos-
loss[125] with administration of nicotine. The therpetic neuralgia in aged people often presents as
dopaminergic nigrostriatal pathway is rich in nico- continuous burning or intense paroxysmal pain last-
tine receptors and in vitro studies have shown that ing several months and may become severe and
local application of nicotine at the nigrostriatal ter- disabling. Treatments such as tricyclic antidepres-
minals increases the exocytosis of dopamine.[126] sants, antiepileptics and opioids are sometimes use-
Moreover, cholinergic cell loss has been described ful for these conditions but not devoid of adverse
in the basal forebrain, parietal, frontal and temporal systemic effects, particularly in aged patients. Nau-
cortices as well as in the hippocampus of patients sea, constipation, urinary difficulties, sedation and
with PD,[127] and it has been suggested that this dizziness are frequent complaints in patients taking
depletion could be associated with cognitive deficits these medications and may lead to drug withdrawal.
frequently observed in this disease.[128] Three con- Conversely, use of topical analgesics or anaesthetics
trolled studies[25-27] have evaluated the effect of may provide pain relief with minimal risk of system-
transdermal nicotine on motor symptoms of PD, but ic toxicity. Of these drugs, lidocaine (lignocaine) in
their results were not encouraging, as only a single a 5% concentration patch has been shown to act as a
study reported an improvement.[25] The other studies targeted peripheral analgesic and is specifically in-
reported no effect or even a worsening of motor dicated for the treatment of postherpetic neural-
symptoms.[26,27] Because the positive study also re- gia.[32] Lidocaine acts locally as a sodium channel
ported improved attention and processing speed in antagonist, reducing the frequency of spontaneous
PD,[25] further research has focused on the effects of ectopic nerve discharges generated as a conse-
nicotine on cognition, using a more rigorous meth- quence of sensory nerve fibre damage.[33] Lidocaine
odological design and a larger number of cognitive patch 5% (700 mg/patch), at a dosage of up to three
tests.[28] According to this study, transdermal nico- patches applied for 12 hours/day for 1–28 days,
tine treatment over 25 days, at doses up to 21 mg/ demonstrated efficacy in patients with moderate-to-
day, neither improved nor worsened cognitive func- severe postherpetic neuralgia, significantly improv-
tioning in 22 nonsmoking PD patients. The treat- ing pain relief scores and items of the Neuropathic
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Pain Scale.[34,35] The most frequent adverse effects
(affecting about 30% of patients) were self-resolv-
ing mild skin rashes or irritation at the application
site. Up to four patches applied for 18 hours/day or
24 hours/day for 3 consecutive days were safe and
well tolerated.[36] An open-label study of 20 pa-
tients,[37] mean age 75 years, using up to five lido-
caine patches/day for 4–15 years in a compassionate
programme, confirmed the tolerability of this treat-
ment and its long-term efficacy in the elderly. Inter-
estingly, only 40% of these patients reported con-
comitant use of opioids, antiepileptics, corticoste-
roids or tricyclic antidepressants, which meant the
risks of adverse effects or drug-drug interactions
were minimised significantly. Because of these data,
a lidocaine patch is recommended as first-line ther-
apy for the treatment of postherpetic neuralgia, al-
though further studies are needed to compare this
treatment with other active therapies and to deter-
mine the pain characteristics of ‘responder’ patients
(e.g. presence or absence of allodynia).
It is important to note that unsuccessful treatment
of chronic neuropathic pain may be due to the occur-
rence of central sensitisation that may perpetuate the
pain even when peripheral sensory input is absent.
In this case, hyperalgesia and hyperpathia are often
the main complaints. Because glutamate is supposed
to play a role in central sensitisation, ketamine, an
NMDA receptor antagonist with opioid receptor
activity, has been proposed for the treatment of
chronic neuropathic pain and postherpetic neural-
gia.[129,130] In a double-blind, placebo-controlled
study[38] ketamine 50mg and 75mg were adminis-
tered daily by an iontophoretic-assisted TDS in pa-
tients with central neuropathic pain. Although no
significant difference in pain scores was observed
between the ketamine and placebo groups after 1
week of treatment, ketamine 75mg was reported to
improve scores on the Pain Disability Index and
quality of life scales in this study. Therefore, until
further information is available, this therapy can be
 2006 Adis Data Information BV. All rights reserved. Drugs Aging 2006; 23 (5)
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recommended only for refractory chronic neuro- most from this particular route of administration for
pathic pain for which primary and secondary options a number of reasons. First, several transdermal ther-
have been exhausted. apeutic options treat diseases typical of old age or
which have an age-related incidence. Secondly,In some patients, severe and persistent pain, in-
transdermal delivery significantly improves pa-cluding cancer pain and neuropathic pain, may re-
tients’ adherence[1,63] as it reduces the discomfortquire continuous analgesia. In this case, sustained-
associated with multiple administration of drugs andrelease formulations of opioids are the main thera-
eliminates problems with swallowing oral prepara-peutic choice when pain is unresponsive to non-
tions. Thirdly, sustained and constant therapeuticopioid analgesics. Recently, transdermal therapeutic
plasma concentrations increase drug efficacy andsystems including the opioids fentanyl[39,40] and
reduce the need for repeated doses. Finally, the riskbuprenorphine[41,42] have became available and have
of systemic adverse effects can be significantly re-been shown to achieve satisfactory analgesia with
duced. Most transdermal treatments, however, stillminimal requirement for rescue medication in al-
need to be evaluated in long-term studies of largermost half of patients. Tolerability was good and
groups of patients in order to optimise dosage andadverse effects typical of opioids, such as nausea,
administration regimens and to evaluate local andvomiting, constipation and dizziness, were reported
systemic adverse effects associated with prolongedto be comparable with those reported with oral ad-
therapy.ministration. While transdermal fentanyl uses the
reservoir patch technology, transdermal bupre-
Acknowledgementsnorphine is a matrix system in which the substance
is an integral part of the polymer structure of the
Dr Lorenzo Priano received a grant (3/2002) from Fonda-patch. The latter technology is preferable because
zione Italo Monzino Via Torquatto Tasso 14, Milano (Italy).
damage to the patch cannot interfere with the con- The authors have no potential conflicts of interest that are
trolled release of the drug and the possibility of directly relevant to the contents of this manuscript.
overdosing is prevented. Its long-lasting effects and
potential to reduce medication overload and discom- References
fort associated with multiple injections or frequent 1. Stahl SM, Wets KM. Recent advances in drug delivery technol-
ogy for neurology. Clin Neuropharmacol 1988; 11: 1-17oral administration make transdermal opioid deliv-
2. Degim IT, Acarturk F, Erdogan D, et al. Transdermal adminis-ery an option for severe and intractable chronic pain,
tration of bromocriptine. Biol Pharm Bull 2003; 26: 501-5
thereby contributing to improved quality of life in 3. Woitalla D, Muller T, Benz S, et al. Transdermal lisuride
delivery in the treatment of Parkinson’s disease. J Neuralthe elderly.
Transm Suppl 2004; 68: 89-95
4. Benes H. Transdermal lisuride: short-term efficacy and tolera-
5. Conclusions bility study in patients with severe restless legs syndrome.
Sleep Med 2006; 7: 31-5
5. Li GL, de Vries JJ, van Steeg TJ, et al. Transdermal iontophoret-In recent years technologies for the development
ic delivery of apomorphine in patients improved by surfactant
of TDS have made great progress and more mole- formulation pretreatment. J Control Release 2005; 101:
199-208cules for therapeutic use can now be included in
6. Priano L, Albani G, Brioschi A, et al. Transdermal apomorphinemedia for transdermal absorption. In some cases,
permeation from microemulsions: a new treatment in Parkin-
clinical studies show that TDS provide a reliable, son’s disease. Mov Disord 2004; 19: 937-42
7. Priano L, Albani G, Brioschi A, et al. Nocturnal anomalousconstant delivery of drugs and persistent therapeutic
movement reduction and sleep microstructure analysis inplasma levels with good overall tolerability. The parkinsonian patients during 1-night transdermal apomorphine
elderly are the group of patients that can benefit the treatment. Neurol Sci 2003; 24: 207-8
 2006 Adis Data Information BV. All rights reserved. Drugs Aging 2006; 23 (5)
372 Priano et al.
8. The Parkinson Study Group. Defining responder status in a in a healthy sample at risk for dementia. Int Psychogeriatr
clinical trial of the rotigotine transdermal system (SPM-962) in 2001; 13: 465-75
early Parkinson’s disease. Mov Disord 2001; 16: 981-2 25. Kelton MC, Kahn HJ, Conrath CL, et al. The effects of nicotine
9. Metman LV, Gillespie M, Farmer C, et al. Continuous trans- on Parkinson’s disease. Brain Cogn 2000; 43: 274-82
dermal dopaminergic stimulation in advanced Parkinson’s dis- 26. Vieregge A, Sieberer M, Jacobs H, et al. Transdermal nicotine
ease. Clin Neuropharmacol 2001; 24: 163-9 in PD: a randomized, double-blind, placebo-controlled study.
10. Poewe W, Luessi F. Clinical studies with transdermal rotigotine Neurology 2001; 57: 1032-5
in early Parkinson’s disease. Neurology 2005; 65 Suppl. 1: 27. Ebersbach G, Stock M, Muller J, et al. Worsening of motor
S11-4 performance in patients with Parkinson’s disease following
11. Guldenpfennig WM, Poole KH, Sommerville KW, et al. Safety, transdermal nicotine administration. Mov Disord 1999; 14:
tolerability, and efficacy of continuous transdermal 1011-3
dopaminergic stimulation with rotigotine patch in early-stage 28. Lemay S, Chouinard S, Blanchet P, et al. Lack of efficacy of a
idiopathic Parkinson disease. Clin Neuropharmacol 2005; 28: nicotine transdermal treatment on motor and cognitive deficits
106-10 in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psy-
12. Pfeiffer RF. A promising new technology for Parkinson’s dis- chiatry 2004; 28: 31-9
ease. Neurology 2005; Suppl. 1: S6-10 29. Asthana S, Craft S, Baker LD, et al. Cognitive and
13. Stiasny-Kolster K, Kohnen R, Schollmayer E, et al., for the neuroendocrine response to transdermal estrogen in postme-
Rotigotine Sp 666 Study Group. Patch application of the nopausal women with Alzheimer’s disease: results of a place-
dopamine agonist rotigotine to patients with moderate to ad- bo-controlled, double-blind, pilot study. Psychoneuroendocri-
vanced stages of restless legs syndrome: a double-blind, place- nology 1999; 24: 657-77
bo-controlled pilot study. Mov Disord 2004; 19: 1432-8 30. Baker L, Sambamurti K, Craft S, et al. 17β-estradiol reduces
14. Coelho F, Birks J. Physostigmine for Alzheimer’s disease. plasma Aβ40 for HRT-naive postmenopausal women with
Cochrane Database Syst Rev 2001; (2): CD001499 Alzheimer disease: a preliminary study. Am J Geriatr Psychia-
try 2003; 11: 239-4415. Moller H-J, Hampel H, Hegerl U, et al. Double-blind, random-
ized, placebo-controlled clinical trial on the efficacy and toler- 31. Hall KA, Keks NA, O’Connor DW. Transdermal estrogen
ability of a physostigmine patch in patients with senile demen- patches for aggressive behavior in male patients with demen-
tia of the Alzheimer type. Pharmacopsychiatry 1999; 32: tia: a randomized, controlled trial. Int Psychogeriatr 2005; 17:
99-106 165-78
16. Sathyan G, Ritschel WA, Hussain AS. Transdermal delivery of 32. Davies PS, Galer BS. Review of lidocaine patch 5% studies in
tacrine: I. identification of a suitable delivery vehicle. Int J the treatment of postherpetic neuralgia. Drugs 2004; 64:
Pharm 1995; 114: 75-83 937-47
17. Jaskari T, Vuorio M, Kontturi K, et al. Controlled transdermal 33. Chabal C, Russell LC, Burchiel KJ. The effect of intravenous
iontophoresis by ion-exchange fiber. J Control Release 2000; lidocaine, tocainide, and mexiletine on spontaneously active
67: 179-90 fibers originating in rat sciatic neuromas. Pain 1989; 38: 333-8
18. Tse FL, Laplanche R. Absorption, metabolism, and disposition 34. Argoff CE, Galer BS, Jensen MP, et al. Effectiveness of the
of [14C] SDZ ENA 713, an acetylcholinesterase inhibitor, in lidocaine patch 5% on pain qualities in three chronic pain
minipigs following oral, intravenous, and dermal administra- states: assessment with the Neuropathic Pain Scale. Curr Med
tion. Pharm Res 1998; 15: 1614-20 Res Opin 2004; 20: S21-8
19. Muhlack S, Przuntek H, Muller T. Transdermal rivastigmine 35. Galer BS, Jensen MP, Ma T, et al. The lidocaine patch 5%
treatment does not worsen impaired performance of complex effectively treats all neuropathic pain qualities: results of a
motions in patients with Alzheimer’s disease. Pharmacop- randomized, double-blind, vehicle-controlled, 3-week efficacy
sychiatry 2006; 39: 16-9 study with use of the neuropathic pain scale. Clin J Pain 2002;
18: 297-30120. ClinicalTrials.gov. A service of the U.S. Institutes of Health
developed by the National Library of Medicine [online]. 36. Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability
Available from URL: http://clinicaltrials.gov/ct/showNCT of the lidocaine patch 5%, a targeted peripheral analgesic: a
00099242 [Accessed 2006 Jun 12] review of the literature. J Clin Pharmacol 2003; 43: 111-7
21. Novartis. Clinical trials information [online]. Available from 37. Galer BS, Gammaitoni AR. More than 7 years of consistent
URL: http://www.novartisclinicaltrials.com/etrials/home.do neuropathic pain relief in geriatric patients [letter]. Arch Intern
[Accessed 2006 Jun 12] Med 2003; 163: 628
22. Snaedal J, Johannesson T, Jonsson JE, et al. The effects of 38. Vranken JH, Dijkgraaf MG, Kruis MR, et al. Iontophoretic
nicotine in dermal plaster on cognitive functions in patients administration of S(+)-ketamine in patients with intractable
with Alzheimer’s disease. Dementia 1996; 7: 47-52 central pain: a placebo-controlled trial. Pain 2005; 118: 224-31
23. White HK, Levin ED. Four-week nicotine skin patch treatment 39. Mystakidou K, Katsouda E, Tsilika E, et al. Transdermal thera-
effects on cognitive performance in Alzheimer’s disease. peutic fentanyl-system (TTS-F). In Vivo 2004; 18: 633-42
Psychopharmacology 1999; 143: 158-65 40. Mystakidou K, Parpa E, Tsilika E, et al. Long-term management
24. Howe MN, Price IR. Effects of transdermal nicotine on learn- of noncancer pain with transdermal therapeutic system-
ing, memory, verbal fluency, concentration, and general health fentanyl. J Pain 2003; 4: 298-306
 2006 Adis Data Information BV. All rights reserved. Drugs Aging 2006; 23 (5)
Transdermal Treatment Options for Neurological Disorders 373
41. Sittl R. Transdermal buprenorphine in the treatment of chronic multicenter, double-blind, randomized, placebo-controlled tri-
pain. Expert Rev Neurother 2005; 5: 315-23 al. Tolcapone Fluctuator Study Group I. Neurology 1997; 48:
81-742. Likar R, Sittl R. Transdermal buprenorphine for treating noci-
ceptive and neuropathic pain: four case studies. Anesth Analg 60. Syed N, Murphy J, Zimmerman T, et al. Ten years’ experience
2005; 100: 781-5 with enteral levodopa infusions for motor fluctuations in
Parkinson’s disease. Mov Disord 1998; 13: 336-843. Olanow CW, Watts RL, Koller W. An algorithm (decision tree)
for the management of Parkinson’s disease: treatment guide- 61. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking
lines. Neurology 2001; 56: S1-88 day apomorphine in the long term treatment of levodopa
induced interdose dyskinesias in Parkinson’s disease. J Neurol44. Albanese A, Bonuccelli U, Brefel C, et al. Consensus statement
Neurosurg Psychiatry 1998; 64: 573-6on the role of acute dopaminergic challenge in Parkinson’s
disease. Mov Disord 2001; 16: 197-201 62. Stocchi F, Ruggieri S, Vacca L, et al. Prospective randomized
trial of lisuride infusion versus oral levodopa in patients with45. van Laar T, van der Geest R, Danhof M, et al. Stepwise
Parkinson’s disease. Brain 2002; 125: 2058-66intravenous infusion of apomorphine to determine the thera-
peutic window in patients with Parkinson’s disease. Clin 63. Pfeiffer RF. Potential of transdermal drug delivery in Parkin-
Neuropharmacol 1998; 2: 152-8 son’s disease. Drugs Aging 2002; 19: 561-70
46. Nutt JG, Carter JH, Van Houten L, et al. Short- and long- 64. Sitruk-Ware R. Transdermal application of steroid hormones for
duration responses to levodopa during the first year of contraception. J Steroid Biochem Mol Biol 1995; 53: 247-51
levodopa therapy. Ann Neurol 1997; 42: 349-55 65. Berner B, John VA. Pharmacokinetic characterisation of trans-
47. Hauser RA, Koller WC, Hubble JP, et al. Time course of loss of dermal delivery systems. Clin Pharmacokinet 1994; 26:
clinical benefit following withdrawal of levodopa/carbidopa 121-34
and bromocriptine in early Parkinson’s disease. Mov Disord 66. Martin GE, Williams M, Pettibone DJ, et al. Pharmacologic
2000; 15: 485-9 profile of a novel potent direct-acting dopamine agonist, (+)-4-
48. Hughes AJ, Frankel JP, Kempster PA, et al. Motor response to propyl-9-hydroxynaphthoxazine [(+)-PHNO]. J Pharmacol
levodopa in patients with parkinsonian motor fluctuations: a Exp Ther 1984; 230: 569-76
follow-up study over three years. J Neurol Neurosurg Psychia- 67. Rupniak NMJ, Tye SJ, Jennings CA, et al. Antiparkinsonian
try 1994; 57: 430-4 efficacy of a novel transdermal delivery system (+)-PHNO in
49. Fahn S, Oakes D, Shoulson I, et al., for the Parkinson Study MPTP-treated squirrel monkeys. Neurology 1989; 39: 329-35
Group. Levodopa and the progression of Parkinson’s disease. 68. Coleman RJ, Lange KW, Quinn NP, et al. The antiparkinsonian
N Engl J Med 2004; 351: 2498-508 actions and pharmacokinetics of (+)-4-propyl-9-hydrox-
50. Calon F, Grondin R, Morissette M, et al. Molecular basis of ynaphthoxazine (+PHNO): preliminary results. Mov Disord
levodopa-induced dyskinesias. Ann Neurol 2000; 47: S70-8 1989; 4: 129-38
51. Hardoff R, Sula M, Tamir A, et al. Gastric emptying time and 69. Ahlskog JE, Muenter MD, Bailey PA, et al. Parkinson’s disease
gastric motility in patients with Parkinson’s disease. Mov monotherapy with controlled release MK-458 (PHNO): doub-
Disord 2001; 16: 1041-7 le-blind study and comparison to carbidopa/levodopa. Clin
Neuropharmacol 1991; 14: 214-2752. Djaldetti R, Baron J, Ziv I, et al. Gastric emptying in Parkin-
son’s disease: patients with and without response fluctuations. 70. Smith LA, Jackson MG, Bonhomme C, et al. Transdermal
Neurology 1996; 46: 1051-4 administration of piribedil reverses MPTP induced motor defi-
cits in the common marmoset. Clin Neuropharmacol 2000; 23:53. Pincus JH, Barry K. Protein redistribution diet restores motor
133-42function in patients with dopa-resistant ‘off’ periods. Neurolo-
gy 1988; 38: 481-3 71. Montestruct JL, Ziegler M, Rascol O, et al. A randomized,
double-blind study of a skin patch of a dopamine agonist,54. DeLong MR, Crutcher MD, Georgopoulos AP. Relations be-
piribedil, in Parkinson’s disease. Mov Disord 1999; 14: 336-41tween movement and single cell discharge in the substantia
72. MacMahon DG. Use of apomorphine in clinical practice. Advnigra of the behaving monkey. J Neurosci 1983; 3: 1599-606
Neurol 1999; 80: 529-3355. Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor
73. Poewe W, Wenning GK. Apomorphine: an underutilized ther-stimulation in advanced Parkinson’s disease. Trends Neurosci
apy for Parkinson’s disease. Mov Disord 2000; 15: 789-942000; 23: S109-15
74. Gancher S. Pharmacokinetics of apomorphine in Parkinson’s56. Chase TN, Konitsiotis S, Oh JD. Striatal molecular mechanisms
disease. J Neural Transm Suppl 1995; 45: 137-41and motor dysfunction in Parkinson’s disease. Adv Neurol
2001; 86: 355-60 75. Ondo W, Hunter C, Almaguer M, et al. A novel sublingual
apomorphine treatment for patients with fluctuating Parkin-57. Soykan I, Sarosiek I, Shifflett J, et al. Effect of chronic oral
son’s disease. Mov Disord 1999; 14: 664-8domperidone therapy on gastrointestinal symptoms and gastric
emptying in patients with Parkinson’s disease. Mov Disord 76. van Laar T, Jansen EN, Essink AW, et al. Intranasal apomor-
1997; 12: 952-7 phine in parkinsonian on-off fluctuations. Arch Neurol 1992;
49: 482-458. Kurth MC, Adler CH. COMT inhibition: a new treatment strate-
gy for Parkinson’s disease. Neurology 1998; 50: S3-14 77. Hughes AJ, Bishop S, Lees AJ, et al. Rectal apomorphine in
Parkinson’s disease [letter]. Lancet 1991; 337: 11859. Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves
motor function and reduces levodopa requirement in patients 78. van Laar T, Jansen EN, Neef C, et al. Pharmacokinetics and
with Parkinson’s disease experiencing motor fluctuations: a clinical efficacy of rectal apomorphine in patients with Parkin-
 2006 Adis Data Information BV. All rights reserved. Drugs Aging 2006; 23 (5)
374 Priano et al.
son’s disease: a study of five different suppositories. Mov 96. Gustafson L, Edvinsson L, Dahlgren N, et al. Intravenous phy-
Disord 1995; 10: 433-9 sostigmine treatment of Alzheimer’s disease evaluated by psy-
chometric testing, regional cerebral blood flow (rCBF) mea-79. Nyholm D. Pharmacokinetic optimisation in the treatment of
surement, and EEG. Psychopharmacology (Berl) 1987; 93: 31-Parkinson’s disease: an update. Clin Pharmacokinet 2006; 45:
5109-36
97. Thal LJ, Lasker B, Sharpless NS, et al. Plasma physostigmine80. Stocchi F, Berardelli A, Vacca L, et al. Apomorphine infusion
concentrations after controlled-release oral administration [let-and the long-duration response to levodopa in advanced
ter]. Arch Neurol 1989; 46: 13Parkinson’s disease. Clin Neuropharmacol 2003; 26: 151-5
81. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking 98.  Jenike MA, Albert MS, Heller H, et al. Oral physostigmine
day apomorphine in the long term treatment of L-dopa induced treatment for patients with presenile and senile dementia of the
interdose dyskinesias in Parkinson’s disease. J Neurol Alzheimer’s type: a double-blind placebo-controlled trial. J
Neurosurg Psychiatry 1998; 64: 573-6 Clin Psychiatry 1990; 51: 3-7
82. van der Geest R, Danhof M, Bodde HE. Iontophoretic delivery 99. Harrell LE, Jope RS, Falgout J, et al. Biological and neuropsy-
of apomorphine. I: in vitro optimization and validation. Pharm chological characterization of physostigmine responders and
Res 1997; 14: 1798-803 nonresponders in Alzheimer’s disease. J Am Geriatr Soc 1990;
83. van der Geest R, van Laar T, Gubbens-Stibbe JM, et al. 38: 113-22
Iontophoretic delivery of R-apomorphine. II: an in vivo study 100. Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacody-
in patients with Parkinson’s disease. Pharm Res 1997; 14: namic and pharmacokinetic properties, and therapeutic effica-
1804-10 cy in Alzheimer’s disease. Drugs Aging 1994; 4: 510-40
84. van Laar T, van der Geest R, Danhof M. Future delivery systems 101. Kankkunen T, Sulkava R, Vuorio M, et al. Transdermal ionto-
for apomorphine in patients with Parkinson’s disease. In: Stern phoresis of tacrine in vivo. Pharm Res 2002; 19: 705-8
GM, editor. Parkinson’s disease. Advances in Neurology, Vol 102. Newhouse PA, Whitehouse PJ. Nicotinic-cholinergic systems in80. Philadelphia (PA): Lippincott Williams and Wilkins, 1999: Alzheimer’s and Parkinson’s disease. In: Piasecki M, New-535-44 house PA, editors. Nicotine in psychiatry: psychopathology
85. Peira E, Scolari P, Gasco MR. Transdermal permeation of and emerging therapeutics. Washington, DC: American Psy-
apomorphine through hairless mouse skin from microemul- chiatric Press, 2000: 149-181
sions. Int J Pharmaceutics 2001; 226: 47-51 103. Sanberg PR, Silver AA, Shytle RD, et al. Nicotine for the86. Cedarbaum JM. Clinical pharmacokinetics of anti-parkinsonian treatment of Tourette’s syndrome. Pharmacol Ther 1997; 74:drugs. Clin Pharmacokinet 1987; 13: 141-78 21-5
87. Staal-Schreinemachers AL, Lakke JP. Bromocriptine long act- 104. Levin ED, Simon BB, Conners CK. Nicotine effects and atten-ing (LA) 50mg intramuscular (IM) for the on-off phenomenon
tion-deficit/hyperactivity disorder. In: Piasecki M, Newhousein Parkinson’s disease [letter]. Acta Neurol Scand 1987; 75:
PA, editors. Nicotine in psychiatry: psychopathology and441
emerging therapeutics. Washington, DC: American Psychiat-88. Vermesh M, Fossum GT, Kletzky OA. Vaginal bromocriptine:
ric Press, 2000: 203-214pharmacology and effect on serum prolactin in normal women.
105. Jones GM, Sahakian BJ, Levy R, et al. Effects of acute subcuta-Obstet Gynecol 1988; 72: 693-8
neous nicotine on attention, information processing and short-89. Domino EF. Selective full dopamine D1-like (SKF-82958) and
term memory in Alzheimer’s disease. PsychopharmacologyD2 like (N-0923) agonist combination in the MPTP monkey
1992; 108: 485-94
model of hemiparkinsonism. Brain Res Bull 1997; 43: 93-5
106. Rosin RA, Levine MD, Peskind E. Transdermal nicotine for90. Belluzzi JD, Domino EF, May JM, et al. N-0923, a selective
agitation in dementia. Am J Geriatr Psychiatry 2001; 9: 443-4dopamine D2 receptor agonist, is efficacious in rat and monkey
107. Wilson AL, Langley LK, Monley J, et al. Nicotine patches inmodels of Parkinson’s disease. Mov Disord 1994; 9: 147-54
Alzheimer’s disease: pilot study on learning, memory, and91. Happe S, Trenkwalder C. Role of dopamine receptor agonists in
safety. Pharmacol Biochem Behav 1995; 51: 509-14the treatment of restless legs syndrome. CNS Drugs 2004; 18:
108. Barros DM, Ramirez MR, Izquierdo I. Modulation of working,27-36
short- and long-term memory by nicotinic receptors in the92. Michaud M, Dumont M, Paquet J, et al. Circadian variation of
basolateral amygdala in rats. Neurobiol Learn Mem 2005; 83:the effects of immobility on symptoms of restless legs syn-
113-8drome. Sleep 2005; 28 (7): 843-6
109. May-Simera H, Levin ED. NMDA systems in the amygdala and93. Becker R, Giacobini E, Elble R, et al. Potential pharmacother-
piriform cortex and nicotinic effects on memory function.apy of Alzheimer disease: a comparison of various forms of
Brain Res Cogn Brain Res 2003; 17: 475-83physostigmine administration. Acta Neurol Scand Suppl 1988;
116: 19-32 110. Levin ED, Tizabi Y, Rezvani AH, et al. Chronic nicotine and
dizocilpine effects on regionally specific nicotinic and NMDA94. Stern Y, Sano M, Mayeux R. Long-term administration of oral
glutamate receptor binding. Brain Res 2005; 1041: 132-42physostigmine in Alzheimer’s disease. Neurology 1988; 38:
1837-41. 111. Buccafusco JJ, Letchworth SR, Bencherif M, et al. Long-lasting
95. Beller SA, Overall JE, Rhoades HM, et al. Long-term outpatient cognitive improvement with nicotinic receptor agonists: mech-
treatment of senile dementia with oral physostigmine. J Clin anisms of pharmacokinetic-pharmacodynamic discordance.
Psychiatry 1988; 49: 400-4 Trends Pharmacol Sci 2005; 26: 352-60
 2006 Adis Data Information BV. All rights reserved. Drugs Aging 2006; 23 (5)
Transdermal Treatment Options for Neurological Disorders 375
112. Wurtman R, Blusztajn J, Maire J-C. ‘Autocannibalism’ of cho- disease: a randomized controlled trial. JAMA 2000; 283:
line-containing membrane phospholipids in the pathogenesis 1007-15
of Alzheimer’s disease: a hypothesis. Neurochem Int 1985; 7:
123. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for369-72
Alzheimer’s disease in women: randomized, double-blind, pla-
113. Frederick B, Satlin A, Wald LL, et al. Brain proton magnetic
cebo-controlled trial. Neurology 2000; 54: 295-301
resonance spectroscopy in Alzheimer disease: changes after
124. Parain K, Marchand V, Dumery B, et al. Nicotine, but nottreatment with xanomeline. Am J Geriatr Psychiatry 2002; 10:
81-8 cotinine, partially protects dopaminergic neurons against
MPTP-induced degeneration in mice. Brain Res 2001; 890:114. Bodick NC, Offen WW, Shannon HE, et al. The selective
347-50muscarinic agonist xanomeline improves both the cognitive
deficits and behavioral symptoms of Alzheimer disease. 125. Prasad C, Ikegami H, Shimizu I, et al. Chronic nicotine intake
Alzheimer Dis Assoc Disord 1997; 11 Suppl. 4: S16-22 decelerates aging of nigrostriatal dopaminergic neurons. Life
115. Henderson V, Paganini-Hill A, Emanuel C, et al. Estrogen Sci 1994; 54: 1169-84
replacement therapy in older women: comparison between 126. Wonnacott S, Kaiser S, Mogg A, et al. Presynaptic nicotinicAlzheimer’s disease cases and nondemented control subjects.
receptors modulating dopamine release in the rat striatum. EurArch Neurol 1994; 51: 896-900
J Pharmacol 2000; 393: 51-8
116. Baldereschi M, Di-Carlo A, Lepore V, et al. Estrogen-replace-
127. Rinne JO, Myllykyla T, Lonnberg P, et al. A postmortem studyment therapy and Alzheimer’s disease in the Italian Longitudi-
of brain nicotinic receptors in Parkinson’s and Alzheimer’snal Study on Aging. Neurology 1998; 50: 996-1002
disease. Brain Res 1991; 547: 167-70117. McEwen B, Woolley C. Estradiol and progesterone regulate
neuronal structure and synaptic connectivity in adult as well as 128. Shinotoh H, Namba H, Yamaguchi M, et al. In vivo mapping of
developing brain. Exp Geront 1994; 29: 431-6 brain cholinergic function in Parkinson’s disease and progres-
sive supranuclear palsy. Adv Neurol 2001; 86: 249-55118. Xu H, Gouras GK, Greenfield JP, et al. Estrogen reduces
neuronal generation of Alzheimer β-amyloid peptides. Nature 129. Gammaitoni A, Gallagher RM, Welz-Bosna M. Topical
Medicine 1998; 4: 447-51 ketamine gel: possible role in treating neuropathic pain. Pain
119. Ancelin ML, Berr C. Hormonal replacement therapy and Med 2000; 1: 97-100
Alzheimer’s disease. All quiet on the western front? Psychol 130. Quan D, Wellish M, Gilden DH. Topical ketamine treatment ofNeuropsychiatr Vieil 2003; 1: 251-7
postherpetic neuralgia. Neurology 2003; 60: 1391-2
120. Shneider L, Farlow M, Pogoda J. Potential role for estrogen
replacement in the treatment of Alzheimer’s dementia. Am J
Med 1997; 103: 46S-50S
Correspondence and offprints: Dr Lorenzo Priano, Divisione
121. Wang P, Liao S, Liu RS, et al. Effects of estrogen on cognition, di Neurologia e Neuroriabilitazione, IRCCS Istituto Auxo-
mood, and cerebral blood flow in AD. Neurology 2000; 54:
logico Italiano, Ospedale S. Giuseppe, 28921 Intra (VB),2061-6
Casella postale 1, Italy.122. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replace-
E-mail: lorenzopriano@yahoo.itment therapy for treatment of mild-to-moderate Alzheimer
 2006 Adis Data Information BV. All rights reserved. Drugs Aging 2006; 23 (5)
